Calypte Only Company with Full Menu of Tests.
Seite 126 von 144 Neuester Beitrag: 03.03.11 19:06 | ||||
| Eröffnet am: | 08.04.05 22:44 | von: Brokersince1. | Anzahl Beiträge: | 4.592 |
| Neuester Beitrag: | 03.03.11 19:06 | von: schubby1 | Leser gesamt: | 206.702 |
| Forum: | Hot-Stocks | Leser heute: | 120 | |
| Bewertet mit: |  | |||
| Seite: < 1 | ... | 124 | 125 | | 127 | 128 | ... 144 > | ||||
Rec. Time Action Price Volume
9:54:30 AM Trade 0.1 50000
9:54:20 AM Ask 0.11 137200
9:53:20 AM Ask 0.11 137000
9:53:08 AM Trade 0.1 20000
9:52:30 AM Bid 0.1 106600
9:52:30 AM Trade 0.1 15000
9:52:16 AM Ask 0.11 136800
9:51:28 AM Bid 0.1 113100
9:51:28 AM Bid 0.1 106600
9:51:28 AM Trade 0.1 46900
9:51:08 AM Ask 0.11 136600
9:50:48 AM Bid 0.1 160000
9:50:40 AM Bid 0.1 120000
9:50:06 AM Ask 0.11 136400
9:48:28 AM Trade 0.11 3000
9:48:26 AM Ask 0.11 136300
9:46:52 AM Ask 0.11 139300
9:44:16 AM Ask 0.11 139100
9:43:28 AM Bid 0.1 145000
9:43:14 AM Bid 0.1 120000
9:43:14 AM Trade 0.1 20000
9:43:14 AM Trade 0.1 20000
9:42:56 AM Ask 0.11 139000
9:41:22 AM Bid 0.1 126600
9:41:22 AM Trade 0.1 15000
9:41:18 AM Ask 0.11 138900
9:41:18 AM Bid 0.1 135000
9:41:18 AM Trade 0.1 20000
9:41:18 AM Trade 0.1 3000
9:41:18 AM Trade 0.1 27000
9:39:22 AM Ask 0.11 138700
9:39:22 AM Trade 0.1 20000
9:37:32 AM Ask 0.11 138600
9:37:16 AM Trade 0.1 10500
da müsstest du dir schon einen put holen, lach, den es aber wohlweislich nicht gibt.
nimm dir lieber andere werte zum zocken, dass hier sit viel zu heiß! hier kannst du mal bei 0,02$ wieder einsteigen...
jedenfalls betrug der verlust in q-2 3.700.000$. sage und schreibe das 78 fache des umsatzes. das ist einsame spitze.
wie gut dein CC gestern ankam, siehst du ja heute am kurs. die leute werfen eher. lange wird die 0,09$ nicht mehr halten...
es ist immer dasselbe bei diesen ominösen CCs. aber das wirst du eh nicht einsehen wollen...
SCRH Last: 0.013 Change: 0.00(0.00%) Volume: 0 Last Trade: 8/9/06
Der Oberwahnsinntipp der Umsatz nach den Zahlen der helle Wahnsinn
Joelu ,Kaufkurse schreibst du gestern, gibts in Amiland, da werden die gehandelt, weil ich ja zu dumm wäre Aktien "nur in Deutschland zu handeln" hmmm ich wollte welche in Amiland aber da ist kein Handel !???
Sag mal wie kann ich die jetzt ordern?
Danke Lucky
14.jpg
<?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" />
LAKE OSWEGO, Ore., Aug. 10 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (Amex: HIV), medical diagnostic tests manufacturer for the professional point of care (PRO) and over the counter (OTC) segments of the market primarily for the detection of antibodies to the human immunodeficiency virus (HIV), announced today that it has received an order for 100,000 of its over-the-counter (OTC) version of the Aware(TM) Oral Fluid HIV-1/2 Rapid Diagnostic Test.
Joseph and Gionis, Calypte's exclusive distributor in the Middle East, is initially focusing on the United Arab Emirates (UAE) with this order. The value of this order is in excess of $250,000.
Dr. Gionis, President of Joseph and Gionis, commented, "Joseph and Gionis has been actively involved with Calypte since the introduction of this first-ever Over-the-Counter (OTC) HIV test at Arab Health, the largest Healthcare Exhibition in the Middle East, held in Dubai last January. I am pleased to see the progress we are now realizing. This first sizable order will go into the UAE. At the same time, we are continuing to obtain regulatory approvals throughout the region and expect to launch this OTC test into additional countries in the coming months."
Dr. Gionis concluded, "While we are all saddened by the war in the Middle East, HIV/AIDS continues to be a major focus and we expect to exceed our one-year targets -- delivering at least 700,000 tests into a minimum of 7 countries in the region."
Roger I. Gale, Chairman and Chief Executive Officer of Calypte stated, "We are starting to penetrate those markets where we have focused our initial regulatory efforts, including South Africa and now the UAE. It is gratifying to see the results and to be able to focus on the positive challenges of ramping up our manufacturing efforts. I look forward to a having a growing and productive relationship with Joseph and Gionis, as this organization continues to utilize its expertise to facilitate the regulatory process in additional countries within its territory. We will continue to keep you posted as we expand our penetration into the Middle East."
About Joseph and Gionis:
Joseph and Gionis (www.josephandgionis.com ) is a global biotechnology consulting and distribution firm with offices in Newport Beach, California and the UAE, specializing in new scientific developments which contribute to public health and welfare.
Joseph and Gionis is Calypte's exclusive distributor for 21 Middle Eastern countries with a population of approximately 465 million people. According to the December 2004 UNAIDS report, there are between 230,000 and 1.5 million adults and children living with HIV within this region, of which nearly half are women.
ttp://www.josephandgionis.com/products.php
Der Aktienkurs wiederspiegelt das Unternehmen keineswegs...
Die Anleger werden auf jeden fall profitieren, daran Arbeite er und sein Team...
Eighth World Congress on Bioethics, Beijing, China.
Dr. Thomas A. Gionis, United States Fulbright Scholar in Law, and President and Chief Executive Officer of Joseph and Gionis, LLC, has been invited to lecture at the Eighth World Congress on Bioethics, Beijing, China.
The World Congress meeting will be held during August, 2006, Beijing.
Dr. Gionis’ presentation will include information from a new database developed concerning human subject violations in the United States. Dr. Gionis’ research and presentation includes an analysis of approximately 3,150 human research subject violations in the United States between 2000-2004. Dr. Gionis completed this research as Chairman, Joint Study Committee on Clinical Research Ethics (JSCCRE)(www.clinicalresearchethics.com).
JSCCRE is a joint cooperative effort of the Fulbright Academy of Science and Technology and the American Board of Healthcare Law and Medicine.
Lies Bitte auch das, was zwischen den Zeilen steht......... ; )
Calypte braucht max. 18 Monate noch bis all der Businessplan realisiert wird...
 OttomanRosend. | 09.08.06 11:27   |
http://globalhealth.org/news/article/7748
Gates Foundation Contributes $500 Million to Global Fund
Aug. 9, 2006
Global Fund Press Release
GENEVA - The Global Fund to Fight AIDS, Tuberculosis and Malaria announced today that it has received a contribution of US$ 500 million over five years from the Bill & Melinda Gates Foundation.
"The Global Fund is one of the most important health initiatives in the world today," said Bill Gates, Co-Chair of the Gates Foundation. "The Global Fund has an excellent track record, and we need to do everything we can to support its continued success, which will save millions of lives."
The announcement comes the week before more than 25,000 researchers, health workers, advocates, and policymakers meet in Toronto to discuss progress and prospects in the fight against AIDS.
"We are extremely grateful to the Gates Foundation for this show of confidence in the Global Fund," said Richard Feachem, Executive Director of the Global Fund. "The Global Fund has proven itself to be an effective way to reach millions of people with urgently-needed medicines and other services. This new commitment by the Gates Foundation will enable us to reach millions more."
"The Gates Foundation has played an important role in making the Global Fund the effective and innovative public/private partnership it is today," said Dr Carol Jacobs, Chairman of the Global Fund's Board. "I hope that other donors, especially those from the private sector, will come together to ensure long-term, sustainable financing for the Global Fund."
Since its launch four years ago, the Global Fund has become a major funder of global efforts to combat AIDS, tuberculosis, and malaria. With grants from the Global Fund, 132 countries have begun to produce substantial results, including 544,000 people provided with life-extending HIV/AIDS treatment, more than 1.4 million people treated for TB, and more than 11 million bed nets distributed to protect children from malaria.
"As we move from crisis management to a sustained AIDS response, we will continue to rely on the Global Fund as the best model to provide strategic and predictable funding," said Dr Peter Piot, Executive Director, UNAIDS. "A fully-funded Global Fund is absolutely critical to the AIDS response. Without it, it will be difficult to turn all of the good ideas and strategic plans into reality on the ground."
"The Global Fund has helped drive progress on AIDS, TB, and malaria that was unthinkable just a few years ago," said Melinda Gates, Co-Chair of the Gates Foundation. "This is a funding model that works, and the need is great. We hope all donors - public and private, large and small - will step up their support and make long-term commitments."
"The impact of the Global Fund can be seen in towns and villages throughout Rwanda," said President Paul Kagame of Rwanda. "Thousands of people who would otherwise be dead are healthy and working to build a better future for their families and our country. The Global Fund has provided us with the support we need to drive back AIDS and other diseases, and I am happy to see that this contribution will help it continue to do so for years to come."
"With the support of the Global Fund, Tanzania has begun to make inroads against the terrible toll of the three diseases," said Lucy Ng'ang'a, Executive Director of the Eastern African National Network of AIDS Service Organizations. "Children are sleeping safely under protective bed nets, TB patients are being cured, and people with AIDS are receiving medications that can keep them healthy for decades. The Gates Foundation's new contribution to the Global Fund will help us to save many more lives in Tanzania, and in our neighboring countries in Eastern Africa."
The Gates Foundation grant is structured so that US$ 100 million will be provided each year from 2006 through 2010. The contributions for 2006 and 2007 will be available to support the Global Fund's sixth round of financing, which is slated to be approved by the Global Fund's board in November.
"With this support, the Global Fund needs an additional US$ 500 million to fully fund all of the new grants that we expect to approve in our sixth round of funding," said Richard Feachem. "With more resources, we can ensure that all high-quality, urgently-needed programs have the financial support they need to save lives."
The Gates Foundation's contribution comes on the eve of the 16th International AIDS Conference in Toronto, the biennial gathering to assess the status of the pandemic and stake out global priorities. Bill and Melinda Gates will speak at the opening ceremony of the conference on August 13.
"The theme of the International AIDS Conference is ‘Time to Deliver,'" said Dr Mark Wainberg, co-chair of the conference. "The theme underscores the urgency of bringing effective HIV prevention, care, and treatment to communities the world over, and the need for stakeholders to fulfill their commitments, be they financial, programmatic, or political. I applaud the Global Fund and the Gates Foundation for taking the challenge of the conference theme to heart."
Today's grant brings the Gates Foundation's total support for the Global Fund to US$ 650 million. The foundation pledged US$ 100 million to the Global Fund in 2001, and an additional US$ 50 million in 2004.
For this Press Release, visit:
http://www.theglobalfund.org/en/media_center/press/pr_060809.asp
Bill & Melinda Gates Foundation
http://www.gatesfoundation.org/
The Global Fund
http://www.theglobalfund.org/
1) hast du wohl noch nie in den staatengekauft, ansonsten hättest du gestern locker zu 0,013$ kaufen können
2) und das ist wohl das weitaus größere problem: nach deinen kopflosen harakiri-einsätzen in caly hast du wohl auch kein geld mehr nochmals iregendeine andere aktie zu kaufen...muhahahahah
merke: lieber eine aktie mit wenig umsatz halten, die den wert aber hält, als eine aktie, die zwar sehr liquide ist, aber dafür ständig ihren wert verliert, GALE?
muhahhaahaha
das ding ist doch dermassenn ausgelutscht und überstrapaziert. du versuchst hier doch mir und allen anderen, vor allem dir selber, ein "X" für ein "U" vorzumachen.
businesspläne gab es schon 2003 und da sagte man, man wolle 2004 profitabel sein, spätestens 2005. was jetzt ist, siehst du ja:
das desaströseste quartalsergebnis seit vielen, vielen jahren. ich glaube nicht mal beim winding-down im april 2002 waren die zahlen soooooo schlecht.
wie oft willst du die ammen-märchen und versprechungen von caly noch glauben???
dir glaubt doch kein mensch mehr. du trägst mit deinen ausführungen nicht zur widerspiegelung der gegenwärtigen lage bei. man könnte meinen, du sprchst von trinity oder orasure mit millionen-umsätzen und gewinnen.
werde mal wach, junge, komm zu dir?
wieviel versprechungen müssen wir von caly noch hören????? wieviel CCs swillst du dir noch reinziehen, frei nach dem motto: "heute geht es los"
du merkst doch, dass elbst die dummen amis sich nicht mehr so verarschen lassen, nach der umsatzmeldung über 250.000$ gestern fiel der kurs zeitweilig sogar...und erwird weiter fallen, bei dem was caly monatlich und quartärlich an kohle verbrennt.
die akitenausgaben machen euch fertig. in 18 monaten gibt es dein kapital nicht mehr: aufgefressen von der dilution und vom RS...und wieder wird es dann heißen: jetzt brauchen wir nochmal 2 jahre, bis zum durchbruch!
oh mann broker, was hast du nur mit deinem ganzen geld gemacht...
| Calypte Presents Next Generation HIV Rapid Test at XVI International AIDS Conference |
| Data on Aware2(TM) HIV-1/2 Rapid Test Research Equals or Exceeds U.S. FDA Sensitivity Standards LAKE OSWEGO, Ore., Aug. 14 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (Amex: HIV; the "Company"), medical diagnostic tests manufacturer for the professional point of care (PRO) and over the counter (OTC) segments of the market primarily for the detection of antibodies to the human immunodeficiency virus (HIV) announced today that it will present an abstract entitled "Initial evaluations of a novel rapid test for HIV-1/2 antibodies in blood or oral fluid," Abstract: CDB0076, on its research to develop a new HIV 1/2 rapid test format for use on whole blood and plasma and oral fluid specimens, at the XVI International AIDS Conference in Toronto, Canada on August 13th-18th. The data contained in the Abstract relates to the Company's second-generation rapid testing platform (Aware2(TM) prototype, which it is currently being developed as an HIV screening test. The unique platform, is based on technology licensed from Ani Biotech Oy of Finland, and allows the Company to enter new markets, including the U.S., where its current Aware(TM) line of rapid tests is not available. The Company said that preliminary results of an internally-conducted study for the Aware2(TM) HIV-1/2 rapid blood test's sensitivity equals or exceeds that of most U.S. FDA approved EIA tests. The Company's current Aware(TM) HIV-1/2 rapid blood and oral fluid tests also exceed most U.S. FDA approved EIA tests. The study demonstrated excellent concordance for matched blood- based and oral fluid specimens with the Aware2(TM) HIV-1/2 prototype test. These findings are the first step in what the Company hopes will culminate in a formal submission to the U.S. FDA for its Aware2(TM) HIV-1/2 rapid BSP (blood) and OMT (oral fluid) tests. Dr. Ron Mink, Calypte's Chief Scientific Officer, stated, "The data we have assembled are very encouraging, in terms of pre-clinical performance characteristics. The test is easy to use and versatile, demonstrated by its ability to detect antibodies to HIV in either oral fluid or blood. The visualizing agent is not part of the test strip, which differentiates it from lateral flow HIV tests currently available and appears to improve sensitivity. We are pleased to be able to share our findings with participants at the XVI International AIDS Conference in Toronto." Roger I. Gale, Calypte's Chairman and Chief Executive Officer commented, "As Dr. Mink noted, the initial results are encouraging. This format is quite sensitive. The Aware2(TM) line is an important opportunity for us. An U.S. FDA advisory panel has recently supported the development of a process to bring a HIV OTC test to the U.S. market and the Aware2(TM) platform is particularly suitable for OTC applications." Mr. Gale continued, "Calypte is uniquely poised to deliver to the U.S. OTC markets rapid tests for HIV and other diseases of public health interest. We plan to use the Aware2(TM) platform to develop a line of diagnostic tests for STDs, with the initial test expected to be syphilis. Initial feasibility research is underway in collaboration with the Centers for Disease Control and Prevention (CDC)." About XVI International AIDS Conference: This Conference (http://www.aids2006.org), which is held every two years, is the world's largest HIV/AIDS conference. It is being held in Toronto Canada from August 13-18, 2006. Its purpose is to provide an international, open and independent forum for the exchange of ideas, knowledge and research on HIV/AIDS -- to inform, as well as to strengthen prevention, treatment and care efforts worldwide. An estimated 20,000 participants including scientists, health care providers, political, community and business leaders, journalists, government, non-governmental and intergovernmental representatives, and people living with HIV/AIDS are expected to attend. Calypte will have a commercial exhibit at the conference, where its products will be available for inspection to potential customers and will have its scientists available to answer questions about its newest technology. The Conference program includes abstract-driven oral and poster sessions, controversies and common ground sessions, bridging sessions, symposia and skills building workshops, along with innovative mechanisms to broaden the reach and impact of this event, particularly in the developing world where the epidemic is most entrenched. About Calypte Biomedical: Calypte Biomedical Corporation (http://www.calypte.com) is a U.S.-based healthcare company focused on the development and commercialization of diagnostic testing products for the detection of sexually transmitted diseases such as the HIV-1 BED Incidence EIA and new diagnostic test products for the rapid detection of HIV and other sexually transmitted diseases, several of which do not require blood samples. Calypte believes there is a significant need for rapid detection of such diseases globally to control their proliferation, particularly in developing countries, which lack the medical infrastructure to support laboratory-based testing. Calypte believes that testing for HIV and other sexually transmitted infectious diseases may make important contributions to public health, and could increase the likelihood of treating those with undetected HIV and other sexually transmitted diseases. Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, the Company's ability to develop and commercialize its test products, obtain additional financing, if and as needed, and access funds from its existing financing arrangements that will allow it to continue its current and future operations and whether demand for its test products in domestic and international markets will generate sufficient revenues to achieve positive cash flow and profitability. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-KSB for the year ended December 31, 2005 and its subsequent filings with the SEC. Company Contact: Investor Relations Contact: Theodore R. Gwin, Tim Clemensen, Chief Financial Officer Rubenstein Investor Relations (971) 204-0282 Phone: (212) 843-9337 email: tgwin@calypte.com email: tclemensen@rubensteinir.comSOURCE Calypte Biomedical Corporation -0- 08/14/2006 /CONTACT: Company Contact: Theodore R. Gwin, Chief Financial Officer, ofCalypte Biomedical Corporation, +1-971-204-0282, tgwin@calypte.com; InvestorRelations: Tim Clemensen, of Rubenstein Investor Relations for CalypteBiomedical Corporation, +1-212-843-9337, tclemensen@rubensteinir.com/ /Web site: http://www.calypte.com http://www.aids2006.org / (HIV)CO: Calypte Biomedical CorporationST: Oregon, CanadaIN: BIO MTC HEA IDCSU: SVY TDSAM-- NYM087 --9578 08/14/2006 07:30 EDT http://www.prnewswire.com |
 |
| Calypte Presents Next Generation HIV Rapid Test at XVI International AIDS Conference |
| Data on Aware2(TM) HIV-1/2 Rapid Test Research Equals or Exceeds U.S. FDA Sensitivity Standards LAKE OSWEGO, Ore., Aug. 14 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (Amex: HIV; the "Company"), medical diagnostic tests manufacturer for the professional point of care (PRO) and over the counter (OTC) segments of the market primarily for the detection of antibodies to the human immunodeficiency virus (HIV) announced today that it will present an abstract entitled "Initial evaluations of a novel rapid test for HIV-1/2 antibodies in blood or oral fluid," Abstract: CDB0076, on its research to develop a new HIV 1/2 rapid test format for use on whole blood and plasma and oral fluid specimens, at the XVI International AIDS Conference in Toronto, Canada on August 13th-18th. The data contained in the Abstract relates to the Company's second-generation rapid testing platform (Aware2(TM) prototype, which it is currently being developed as an HIV screening test. The unique platform, is based on technology licensed from Ani Biotech Oy of Finland, and allows the Company to enter new markets, including the U.S., where its current Aware(TM) line of rapid tests is not available. The Company said that preliminary results of an internally-conducted study for the Aware2(TM) HIV-1/2 rapid blood test's sensitivity equals or exceeds that of most U.S. FDA approved EIA tests. The Company's current Aware(TM) HIV-1/2 rapid blood and oral fluid tests also exceed most U.S. FDA approved EIA tests. The study demonstrated excellent concordance for matched blood- based and oral fluid specimens with the Aware2(TM) HIV-1/2 prototype test. These findings are the first step in what the Company hopes will culminate in a formal submission to the U.S. FDA for its Aware2(TM) HIV-1/2 rapid BSP (blood) and OMT (oral fluid) tests. Dr. Ron Mink, Calypte's Chief Scientific Officer, stated, "The data we have assembled are very encouraging, in terms of pre-clinical performance characteristics. The test is easy to use and versatile, demonstrated by its ability to detect antibodies to HIV in either oral fluid or blood. The visualizing agent is not part of the test strip, which differentiates it from lateral flow HIV tests currently available and appears to improve sensitivity. We are pleased to be able to share our findings with participants at the XVI International AIDS Conference in Toronto." Roger I. Gale, Calypte's Chairman and Chief Executive Officer commented, "As Dr. Mink noted, the initial results are encouraging. This format is quite sensitive. The Aware2(TM) line is an important opportunity for us. An U.S. FDA advisory panel has recently supported the development of a process to bring a HIV OTC test to the U.S. market and the Aware2(TM) platform is particularly suitable for OTC applications." Mr. Gale continued, "Calypte is uniquely poised to deliver to the U.S. OTC markets rapid tests for HIV and other diseases of public health interest. We plan to use the Aware2(TM) platform to develop a line of diagnostic tests for STDs, with the initial test expected to be syphilis. Initial feasibility research is underway in collaboration with the Centers for Disease Control and Prevention (CDC)." About XVI International AIDS Conference: This Conference (http://www.aids2006.org), which is held every two years, is the world's largest HIV/AIDS conference. It is being held in Toronto Canada from August 13-18, 2006. Its purpose is to provide an international, open and independent forum for the exchange of ideas, knowledge and research on HIV/AIDS -- to inform, as well as to strengthen prevention, treatment and care efforts worldwide. An estimated 20,000 participants including scientists, health care providers, political, community and business leaders, journalists, government, non-governmental and intergovernmental representatives, and people living with HIV/AIDS are expected to attend. Calypte will have a commercial exhibit at the conference, where its products will be available for inspection to potential customers and will have its scientists available to answer questions about its newest technology. The Conference program includes abstract-driven oral and poster sessions, controversies and common ground sessions, bridging sessions, symposia and skills building workshops, along with innovative mechanisms to broaden the reach and impact of this event, particularly in the developing world where the epidemic is most entrenched. About Calypte Biomedical: Calypte Biomedical Corporation (http://www.calypte.com) is a U.S.-based healthcare company focused on the development and commercialization of diagnostic testing products for the detection of sexually transmitted diseases such as the HIV-1 BED Incidence EIA and new diagnostic test products for the rapid detection of HIV and other sexually transmitted diseases, several of which do not require blood samples. Calypte believes there is a significant need for rapid detection of such diseases globally to control their proliferation, particularly in developing countries, which lack the medical infrastructure to support laboratory-based testing. Calypte believes that testing for HIV and other sexually transmitted infectious diseases may make important contributions to public health, and could increase the likelihood of treating those with undetected HIV and other sexually transmitted diseases. Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, the Company's ability to develop and commercialize its test products, obtain additional financing, if and as needed, and access funds from its existing financing arrangements that will allow it to continue its current and future operations and whether demand for its test products in domestic and international markets will generate sufficient revenues to achieve positive cash flow and profitability. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-KSB for the year ended December 31, 2005 and its subsequent filings with the SEC. Company Contact: Investor Relations Contact: Theodore R. Gwin, Tim Clemensen, Chief Financial Officer Rubenstein Investor Relations (971) 204-0282 Phone: (212) 843-9337 email: tgwin@calypte.com email: tclemensen@rubensteinir.comSOURCE Calypte Biomedical Corporation -0- 08/14/2006 /CONTACT: Company Contact: Theodore R. Gwin, Chief Financial Officer, ofCalypte Biomedical Corporation, +1-971-204-0282, tgwin@calypte.com; InvestorRelations: Tim Clemensen, of Rubenstein Investor Relations for CalypteBiomedical Corporation, +1-212-843-9337, tclemensen@rubensteinir.com/ /Web site: http://www.calypte.com http://www.aids2006.org / (HIV)CO: Calypte Biomedical CorporationST: Oregon, CanadaIN: BIO MTC HEA IDCSU: SVY TDSAM-- NYM087 --9578 08/14/2006 07:30 EDT http://www.prnewswire.com |
|
auch wenn du als einer der letzten wenigen die wahrheit konsequent ignorierst:
WARMDUSCHERMELDUNG!
kurzes pop up, dann wieder abverkauf.
naja, wenn euch 0,12$ zum aussteigen reichen...sind ja immerhin schon knapp 30% von 0,0925$ ausgehend.
ihr werdet euren 100%er noch bekommen und wenn er von 0,04$ bis 0,08$ geht, er wird nochmal kommen, die frage ist: wem nutzt das dann noch?
WHO calls for massive increase in global AIDS tests
by Isabel ParenthoenMon Aug 14, 4:38 PM ET
A senior world AIDS expert urged community doctors to crank up testing for the killer virus, bemoaning the "appalling" fact that nine in ten HIV carriers don't know they are infected.
Kevin De Cock, director of the World Health Organisation (WHO) department of HIV/AIDS, told AFP that empowering physicians to test patients could help check the spread of the disease which has already killed 25 million people.
"Only ten percent of people living with HIV in the world are aware of their HIV status," De Cock said on the sidelines of the 16th International AIDS conference in Canada.
"That's appalling. We have to scale up the traditional ways of knowledge, in other words voluntary counselling and testing ... we need innovative ways of doing it."
De Cock said the WHO could not accept that patients were flocking to health centers across the world, but were not being tested for HIV or AIDS.
"We will talk about provider-initiated testing and counselling."
Health officials have long worried carriers of the virus cannot heed calls to take personal responsibility to stop its murderous march across continents, if they don't even know they have the virus.
But officials acknowledge that some people who might suspect they are infected are unwilling to take AIDS tests, fearing discrimination, stigma and an erosion of their own basic rights in often developing societies.
De Cock argued that even as new antiretrovial treatments become more widely available and billions of dollars were poured into the anti-AIDS fight, prevention of new infections remained vital.
"Prevention has to be at the center of our response. We're not going to solve this epidemic just by scaling up treatment," he said.
"We have to provide prevention advice and service to people living with HIV. HIV is transmitted by people living with HIV. We've hardly focused on HIV-infected people at all. We need to do that."
Globally, 12 percent of people who want testing have access to it.
In the adult population, 0.1 percent have taken a test in South and Southeast Asia, compared to 0.2 percent in North America.
The figures are marginally better in Sub Saharan Africa, the region worst blighted by the murderous passage of AIDS, at 2.2 percent.
Another priority for the WHO, is to tackle the terrible problem of HIV and AIDS transmission between mothers and babies -- which though mostly eradicated in the West, is still rampant in the developing world.
"The whole issue of prevention of mother to child transmission is not exclusively an African one but very largely, because such a large proportion of women with HIV are African," De Cock said.
In sub-Saharan Africa, AIDS caused 6.5 percent of deaths of infants younger than five years old in 2003. One infected child in two never reaches the age of two years. Fewer than one pregnant mother in ten gets the treatment which can prevent the transmission of the virus to the baby.
"Every child born with HIV is an illustration of several failures," De Cock said.
"It's the failure of the prevention of HIV infections in young girls and young women, of unwanted pregnancy or pregnancy in an HIV-infected young woman, and the failure of delivery of services to prevent mother-to-child transmission itself."
http://news.yahoo.com/s/afp/20060814/hl_afp/healthaidswho_060814203845
du wirst es wirklich nicht verstehen, wenn es dann aber doch so weit ist, wirst du nur staunen und uns hinterher weinen.........
der einzige, der hier nicht versteht und vor allem nichts einsieht, bist doch du! schau dir an, wo ihr steht. delisting, schlechteste quartalszahlen seit firmenbeginn, aktienflut.
auch staunen und weinen wirst nur du, wenn du irgendwann einmal die nackte wahrheit an dich ranlässt.
denke an deinen eigenen spruch, in etwa so sinngemäß: "deine letzte stunde mit caly kommt schneller als du denkst"